Johnson & Johnson Pharmaceutical Research and Development

Type: Subsidiary
On the web: http://www.jnjpharmarnd.com

If Johnson & Johnson Pharmaceutical Research & Development (J&JPRD) isn't remembered for winning the most descriptive name competition, it will be remembered for providing research and development support for the pharmaceutical business units of Johnson & Johnson. Its main research processes are divided into three franchises: central nervous system and internal medicine; biotech, immunology, and oncology (through J&J subsidiary Centocor); and virology (through Tibotec). Current drugs under development include a treatment for hospital-acquired pneumonia and a painkiller for joint-disease pain.

Officers:
President: Garry Neil
VP Information Management: Biotechnology Research Services

Competitors:
Covance
Pharmaceutical Product Development
Quest Diagnostics

Johnson & Johnson Pharmaceutical Research and Development (J&JPRD) is a subsidiary of Johnson & Johnson that is responsible for discovering and developing pharmaceutical drugs. J&JPRD has research sites located in Raritan, New Jersey, Spring House, Pennsylvania, La Jolla, California, Beerse, Belgium and Toledo, Spain.

J&JPRD was created through the merge of various research organizations including McNeil Pharmaceuticals, Janssen Research Foundation, Three Dimensional Pharmaceuticals and the R. W. Johnson Pharmaceutical Research Institute.

Collaborative Research

In addition to internal research and development activities J&JPRD is also involved in publicly funded collaborative research projects, with other industrial and academic partners. One example in the area of non-clinical safety assessment is the InnoMed PredTox.^[1][2] The company is expanding its activities in joint research projects within the framework of the Innovative Medicines Initiative of EFPIA and the European Commission.^[3]

References

1. ^ Mattes WB (2008), Public consortium efforts in toxicogenomics, Methods Mol Biol. 2008;460:221-38 [1]
2. ^ "InnoMed PredTox Member Organizations". http://www.innomed-predtox.com/consortium/members/. Retrieved on 2008-08-25. 
3. ^ Innovative Medicines Initiative. "IMI Call Topics 2008". IMI-GB-018v2-24042008-CallTopics.pdf. European Commission. http://imi.europa.eu/docs/calls01_en.zip. Retrieved on 2008-08-25. 

External links

• Company website

This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Wikipedia by expanding it.

This entry is from Wikipedia, the leading user-contributed encyclopedia. It may not have been reviewed by professional editors (see full disclaimer)